enVVeno Medical Corporation (NVNO) Stock Score, Valuation & Financial Research

enVVeno Medical Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NVNO

enVVeno Medical Corporation does not currently have a complete Wall Street Score. The stored market price is USD 8.06. These figures are a research snapshot, not a buy or sell recommendation.

What enVVeno Medical Corporation does

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

enVVeno Medical Corporation is a clinical-stage medical device company that does not currently generate revenue from product sales. Its business model focuses on the research, development, and clinical testing of bioprosthetic tissue-based solutions for treating deep venous disease, with the goal of eventually commercializing these devices upon receiving regulatory approval.

Products and services

  • The company is developing the VenoValve, a surgical replacement venous valve, and the enVVe system, a non-surgical, transcatheter-based replacement venous valve system, both designed to treat deep chronic venous insufficiency.

Brands and product families

  • VenoValve — Surgical replacement venous valve for deep chronic venous insufficiency. Source
  • enVVe — Transcatheter-based replacement venous valve system. Source

Customer types

Hospitals and surgical centers; Vascular surgeons and interventional cardiologists.

Suppliers, materials and equipment

  • Contract manufacturers and raw material suppliers — The company relies on third-party suppliers for raw materials and components used in the development and manufacturing of its bioprosthetic devices. Source

Business strengths to evaluate

  • Proprietary bioprosthetic tissue-based technology Source
  • Experienced management team with history of FDA approvals Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Regulatory uncertainty and potential for FDA non-approval Source
  • Reliance on clinical trial success and third-party manufacturing Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NVNO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.06
Market capitalization:
5.6M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -15.72M
Free cash flow:
USD -15.57M
Cash:
USD 2.84M
Total debt:
USD 505K
EPS:
USD -520.08

What stands out

  • Free cash flow is USD -15.57M, negative for the stored period.
  • The balance sheet shows USD 2.84M of cash versus USD 505K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.34M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NVNO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NVNO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NVNO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NVNO to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NVNO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NVNO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.